Rosuvastatin Calcium
Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol. In vivo studies in animals and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic low-density lipoprotein (LDL) receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of very-low-density lipoprotein (VLDL), which reduces the total number of VLDL and LDL particles. It is indicated for Hyperlipidemia and Mixed Dyslipidaemia, Hypertriglyceridemia, Primary Dysbetalipoproteinemia, Homozygous Familial Hypercholesterolemia, Slowing of the Progression of Atherosclerosis, Primary Prevention of CVD.
Rosuvastatin 5mg / 10mg / 20mg / 40mg Tablets.
